Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: July 31, 2003 (Third Quarter of Fiscal 2003)
Business Overview: Cooper operates two primary segments: CooperVision (CVI), which markets specialty contact lenses, and CooperSurgical (CSI), which markets medical devices and surgical instruments for women's healthcare. The company is an accelerated filer with 31,443,498 shares of common stock outstanding as of August 31, 2003.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended July 31, 2003 | Nine Months Ended July 31, 2003 |
|---|---|---|
| Net Sales | $108,442 | $298,824 |
| Gross Profit | $68,632 | $190,419 |
| Gross Margin | 63% | 64% |
| Operating Income | $25,326 | $66,297 |
| Net Income | $18,663 | $47,729 |
| Diluted EPS | $0.58 | $1.49 |
| Cash from Operations (9mo) | $48,147 | |
| Cash and Equivalents (End of Period) | $30,798 | |
| Total Debt | $191,799 (Short-term: $22,744; Long-term: $169,055) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 20% in the quarter and 35% year-to-date compared to the prior year periods. CVI revenue grew 24% (quarter) and 41% (nine months), while CSI revenue grew 4% (quarter) and 16% (nine months).
- Profitability: Operating income surged 49% in the quarter and 48% year-to-date. Net income increased 40% in the quarter and 46% year-to-date.
- Margins: Gross margin improved to 63% in the quarter (from 62%) and 64% year-to-date (from 62%). CSI's margin improvement was significant, rising to 54% from 44% in the prior year quarter, excluding a one-time charge in the prior year.
- Acquisitions: The company completed the acquisition of Prism Enterprises, LP, for approximately $23 million in May 2003. Prism's results are included from the date of acquisition.
- Debt Structure: The company issued $115 million in 2.625% convertible senior debentures in the third quarter. Proceeds were used to repay a significant portion of the revolving line of credit.
Guidance, Outlook, and Risks
- Outlook: Management expects cash on hand and operating cash flows to fund future operations, capital expenditures, dividends, and smaller acquisitions. The effective tax rate (ETR) for fiscal 2003 is projected at 24%, down from 25%, with an expectation of approximately 23% for fiscal 2004.
- R&D Investment: CVI is investing in new research programs for extended wear and improved contact lens technology, with R&D expenses expected to approach $4 million in fiscal 2003.
- Risks and Contingencies:
- Foreign Exchange: The company is exposed to currency fluctuations, particularly the British pound and euro. A strengthening pound resulted in a $1.9 million gain in the first nine months.
- Legal: A trademark dispute with Dioptics Medical Products, Inc. was settled in May 2003; a provision was recorded in the first quarter covering all associated costs.
- Market Risk: Exposure to interest rate changes on variable rate debt, partially mitigated by the new fixed-rate convertible debentures.
- Unusual Items: The prior year's CSI gross margin was impacted by a $2 million charge related to the phase-out of the Cerveillance Colposcope system. The current period does not include similar charges.
Investor Verification Checklist
- Acquisition Integration: Verify the integration progress and revenue contribution of the Prism Enterprises acquisition.
- Convertible Debt Terms: Review the conversion terms of the $115 million debentures (conversion price approx. $44.40) and potential dilution impact.
- Tax Rate Sustainability: Confirm the assumptions behind the projected 24% effective tax rate and the impact of the global trading arrangement on future cash tax payments.
- Inventory Levels: Monitor inventory levels, which increased to $82.9 million, to ensure they align with sales growth and do not indicate obsolescence risks.
- Constant Currency Growth: Distinguish between reported growth and constant currency growth (approx. 17% for CVI) to assess organic performance versus currency effects.